Report Key Points Summary 1. Report Industry Investment Rating No industry investment rating is provided in the content. 2. Report's Core View - From September 1 - 6, 2025, the convertible bond market repaired. Medium - sized varieties gained more attention, while the trading volume proportion of small - sized ones declined, indicating a shift in capital preference. Valuations stretched overall, with the median market price oscillating upwards and remaining at a high level. The implied volatility rose slightly, reflecting increased market optimism [2][6]. - In the industry, power equipment and light manufacturing performed well, while communication and computer sectors faced pressure. Trading was concentrated in electronics, power equipment, and machinery. Individual bonds were still driven by underlying stocks, and some callable bonds achieved high returns. Overall, medium - sized convertible bonds have relative advantages in terms of scale and scarcity. It is advisable to focus on individual bonds with underlying stock support and stable fundamentals, while being vigilant about short - term volatility risks in highly crowded areas [2][6]. 3. Summary by Related Catalogs Market Theme and Style Shift - There may be a trend in the equity market of switching from small - cap to mid - and large - cap indices. Since August 2025, the trading volume proportion of small - cap indices has declined, while that of mid - and large - cap indices has increased. The rolling excess returns of mid - and large - cap indices have also slightly risen since August 2025 [18]. - The attention to medium - sized convertible bonds has increased. The trading volume proportion of medium - and small - sized convertible bond indices shows a significant negative correlation. The proportion of small - sized indices has been in a downward trend since the end of June 2025, and the 12 - week rolling excess return of medium - sized convertible bonds is on the rise, indicating a possible style shift from small - to medium - sized [20]. - Medium - sized convertible bonds currently have relatively low overall scale compared to the previous high of the median market price. With scarcity and a relatively loose market environment, they may be supported to strengthen. Their valuation is in a reasonable range, with the balance - weighted conversion premium rate at the 31.4% quantile since September 2020 and the median premium rate at the 46.4% quantile [22]. Market Weekly Review - **Equity Market**: A - share major indices oscillated and consolidated, with the ChiNext Index rising against the trend. The large - cap sector showed relative resilience. Main funds continued to flow out, but the outflow pressure eased. On Friday, some funds flowed back, indicating market confidence in the future. Industries showed differentiation, with power equipment, non - ferrous metals and other cyclical and resource products strengthening, while AI and military sectors declined. Trading concentration remained high, with funds concentrated in electronics, power equipment, and computer sectors [10]. - **Convertible Bond Market**: The convertible bond market repaired overall, with large - cap varieties rebounding more prominently and small - cap ones relatively under pressure. Market sentiment improved. Valuations stretched overall, with the median market price oscillating upwards and remaining at a high level. The implied volatility rose slightly, reflecting market optimism. Power equipment and light manufacturing led the rise, while communication and computer sectors were relatively weak. Trading activity was concentrated in power equipment, electronics, and machinery. Individual bonds were mainly driven by underlying stocks, and some callable bonds continued to achieve high returns [10]. - **Primary Market**: The primary market supply was stable. There were no new bond listings, but 6 companies updated their issuance plans, indicating sufficient future reserves. In terms of terms, 4 bonds announced potential downward revisions, 4 announced no downward revisions, and 3 proposed downward revisions. In terms of redemptions, 5 bonds were expected to trigger redemptions, 2 announced no early redemptions, and 5 announced early redemptions [10].

Core Viewpoint - Nanwei Technology has shown a mixed performance in financing activities, with a net financing inflow of 24.62 million yuan last week, ranking 482nd in the market, while experiencing significant capital outflows in recent days [1] Financing Activities - Last week, Nanwei Technology had a total financing buy amount of 189 million yuan and a repayment amount of 164 million yuan [1] - Over the past 5 days, the main capital outflow was 21.46 million yuan, with a decline of 2.02% [1] - Over the past 10 days, the main capital outflow reached 76.54 million yuan, with a decline of 3.92% [1] Company Profile - Suzhou Nanwei Technology Co., Ltd. was established in 2007 and is located in Suzhou, primarily engaged in the manufacturing of chemical raw materials and products [1] - The company has a registered capital of 4,038.15 million yuan and a paid-in capital of 3,561.46 million yuan [1] - The legal representative of the company is Jiang Biwang [1] Investment and Intellectual Property - Nanwei Technology has invested in 16 companies and participated in 43 bidding projects [1] - The company holds 90 trademark registrations and 73 patent registrations, along with 21 administrative licenses [1]

Core Viewpoint - Haoyao Group Co., Ltd. has shown a net financing inflow of 31.4015 million yuan last week, ranking 416th in the market, indicating a moderate interest from investors [1] Financing and Investment Summary - The total financing amount for Haoyao Group last week was 177 million yuan, while the repayment amount was 145 million yuan [1] - Over the past 5 days, the main capital outflow was 21.4667 million yuan, with a decline of 1.72% [1] - Over the past 10 days, the main capital outflow reached 60.8916 million yuan, with a decline of 2.71% [1] Company Profile - Haoyao Group Co., Ltd. was established in 1991 and is located in Harbin, primarily engaged in the pharmaceutical manufacturing industry [1] - The registered capital of the company is 25,212.78976 million yuan, and the paid-in capital is 25,072.19075 million yuan [1] - The legal representative of the company is Lu Chuanyou [1] Business Activities - Haoyao Group has invested in 30 enterprises and participated in 3,232 bidding projects [1] - The company holds 2 trademark registrations and 67 patents, along with 21 administrative licenses [1]

Core Viewpoint - The financing data indicates significant selling pressure on Borui Pharmaceutical, with a net financing sell-out of 220.63 million yuan last week, ranking fourth in the market [1] Financing Activity - Borui Pharmaceutical had a total financing buy amount of 748 million yuan and repayment amount of 969 million yuan last week [1] - Over the past five days, the main capital outflow reached 752 million yuan, with a decline of 13.55% [1] - Over the past ten days, the main capital outflow was 767 million yuan, with a decline of 7.14% [1] Company Profile - Borui Pharmaceutical (Suzhou) Co., Ltd. was established in 2001 and is located in Suzhou, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 422.465 million yuan and a paid-in capital of 220.624827 million yuan [1] - The legal representative of the company is Yuan Jiandong [1] Investment and Intellectual Property - Borui Pharmaceutical has invested in 38 companies and participated in 50 bidding projects [1] - The company holds 121 trademark registrations and 179 patent registrations, along with 36 administrative licenses [1]

Group 1 - The stock price of Yirui Bio is reported at 13.15 yuan, down 2.01% from the previous trading day, with an intraday high of 13.46 yuan and a low of 12.96 yuan, and a trading volume of 114 million yuan [1] - Yirui Bio's main business includes food rapid testing, animal epidemic disease testing, and in vitro diagnostics, with food rapid testing accounting for over 90% of its business [1] - The company is associated with sectors such as chemical pharmaceuticals, smallpox virus prevention, and specialized and innovative enterprises [1] Group 2 - On August 20, Yirui Bio announced that the board decided not to redeem the "Yirui Convertible Bonds" early, and if redemption clauses are triggered again within the next three months, the company will still not exercise its redemption rights [1] - On the same day, the net inflow of main funds was 4.467 million yuan, while the cumulative net outflow of main funds over the past five days was 10.4952 million yuan [1]

Core Viewpoint - Zhejiang Medicine has shown a net financing inflow of 16.134 million yuan last week, ranking 494th in the market, indicating a moderate interest from investors [1] Financing and Investment Summary - The total financing amount for Zhejiang Medicine last week was 265 million yuan, while the repayment amount was 249 million yuan [1] - Over the past 5 days, the main capital outflow was 9.0568 million yuan, with a decline of 0.52% in this period [1] - In the last 10 days, the main capital outflow reached 134 million yuan, reflecting a decline of 3.43% [1] Company Profile - Zhejiang Medicine Co., Ltd. was established in 1997 and is located in Shaoxing City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 961.63775 million yuan, which is also its paid-in capital [1] - The legal representative of the company is Li Nanhang [1] Business Activities - Zhejiang Medicine has made investments in 28 enterprises and participated in 83 bidding projects [1] - The company holds 190 trademark registrations and 27 patents, along with 46 administrative licenses [1]

Group 1 - The stock price of Fuyuan Pharmaceutical closed at 31.67 yuan on August 15, 2025, down 0.66% from the previous trading day [1] - The stock experienced significant volatility, with a high of 32.60 yuan and a low of 30.48 yuan, resulting in an amplitude of 6.65% [1] - The total trading volume for the day was 200,306 hands, with a transaction amount of 628 million yuan [1] Group 2 - Fuyuan Pharmaceutical is primarily engaged in chemical pharmaceuticals and medical devices, covering multiple therapeutic areas including cardiovascular, digestive, and anti-infection [1] - The company is headquartered in Beijing and is one of the stocks included in the Shanghai-Hong Kong Stock Connect [1] - A half-year performance briefing is scheduled for August 22, 2025, where the chairman and general manager will interact with investors online [1] Group 3 - On August 15, 2025, the net outflow of main funds was 36.41 million yuan, accounting for 0.24% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 61.33 million yuan, representing 0.4% of the circulating market value [1]

Market Performance - The three major A-share indices continued to rise, with the Shanghai Composite Index surpassing 3600 points, closing at 3617 points, up 0.96% [1] - The Shenzhen Component Index increased by 0.59%, and the ChiNext Index rose by 0.39% [1] - Total trading volume reached 1.62 trillion yuan, an increase of 976 billion yuan compared to the previous trading day, with over 3900 stocks rising across the market [1] Sector Highlights - PEEK materials saw significant gains, with stocks like Xinhan New Materials and Zhongxin Fluorine Materials hitting the daily limit [1] - The consumer electronics sector also performed well, with stocks such as Furi Electronics and Yidelong reaching the daily limit [1] - The communication equipment sector strengthened, with companies like Dongxin Peace and Changfei Optical Fiber also hitting the daily limit [1] - The automotive parts sector was active, with stocks like Xinquan Co., Hunan Tianyan, and Zhongma Transmission reaching the daily limit [1] - Other notable sectors with strong performance included copper cable high-speed connections, brain-computer interfaces, space station concepts, and plastic products [1] Declining Sectors - The traditional Chinese medicine sector experienced a downturn, with Qizheng Tibetan Medicine hitting the daily limit down [1] - The Kimi concept saw declines, with Wanxing Technology leading the drop [1] - Other sectors with significant declines included recombinant proteins, hepatitis concepts, and chemical pharmaceuticals [1]

Market Performance - On the last trading day of July, all three major A-share indices fell by over 1%, with the Shanghai Composite Index closing below 3600 points at 3573.21, down 1.18% [1] - The Shenzhen Component Index dropped 1.73% to 11009.77, while the ChiNext Index decreased by 1.66% to 2328.31 [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.96 trillion yuan [1] Sector Performance - The sectors that saw gains included liquid cooling IDC, assisted reproduction, Google, biopharmaceuticals, chemical pharmaceuticals, and computers [1] - Conversely, sectors that experienced declines included aquaculture, PTA, iron ore, energy metals, steel, and minor metals [1] Notable Stocks - The AI sector showed strong fluctuations, with Yidian Tianxia (301171) hitting the 20% daily limit up [1] - The liquid cooling server sector performed well, with Sihua New Materials (301489) also reaching the 20% limit up, alongside Yingweike (002837) and Chunz中科技 (603516) [1] - The assisted reproduction sector continued to strengthen, with Gongtong Pharmaceutical (300966) and Anke Biotechnology (300009) both hitting the 20% limit up, while Hanshang Group (600774) also reached the limit [1] - The steel sector faced adjustments, with Baogang Co. (600010) dropping over 8% [1] - The coal sector declined across the board, with Antai Group (600408) falling over 7% [1] Market Outlook - According to Jifeng Investment Advisory, the A-share market is expected to continue a structural trend in August, supported by the intensive disclosure of mid-term performance and ongoing policy efforts, favoring industries with high earnings certainty [1] - Dongfang Securities noted that the current A-share market is in a sustained upward trend with ample trading volume, attracting new capital, and maintaining a cautiously optimistic sentiment without immediate risk of reversal [2]

Market Overview - On June 9, the A-share market saw all three major indices close higher, with the Shanghai Composite Index rising by 0.43% to 3399.77 points, the Shenzhen Component Index increasing by 0.65% to 10250.14 points, and the ChiNext Index up by 1.07% to 2061.29 points. The total trading volume in the Shanghai and Shenzhen markets reached 128.64 billion yuan, an increase of 13.44 billion yuan compared to the previous trading day [1]. Industry Performance - The pharmaceutical sector exhibited the strongest performance on June 9, with chemical pharmaceuticals reaching a nearly four-year high, immunotherapy hitting a two-year high, and weight-loss drugs achieving a one-and-a-half-year high. Other segments such as generic drugs and hepatitis treatments also reached new highs for the year [2]. - In May, at least six domestic innovative pharmaceutical companies announced business development (BD) transactions, primarily involving cross-border cooperation with foreign pharmaceutical companies. Additionally, at the recent ASCO conference, 73 research projects from China were selected for oral presentations, including 11 significant research abstracts [2]. Company Insights - Lingpai Technology, a notable stock on June 9, saw its share price increase by over 10%. The company specializes in the research, production, and sales of new environmentally friendly surface engineering chemicals. In Q1 2025, Lingpai reported an earnings per share of -0.15 yuan and a net profit attributable to shareholders of -26.63 million yuan, with a year-on-year growth rate of 14.54%. The company has completed the research and development of the NCM811 battery chemical system and is actively involved in the new energy vehicle, energy storage, and engineering machinery sectors [4].